BioRestorative Therapies (NASDAQ:BRTX) Posts Earnings Results, Beats Expectations By $0.22 EPS

BioRestorative Therapies (NASDAQ:BRTX) issued its quarterly earnings results on Tuesday. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.22, Zacks reports. BioRestorative Therapies had a negative return on equity of 93.89% and a negative net margin of 2,697.08%. The business had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.30 million.

BioRestorative Therapies Trading Down 3.9 %

BRTX stock traded down $0.06 during mid-day trading on Thursday, hitting $1.48. The stock had a trading volume of 33,333 shares, compared to its average volume of 768,575. The firm has a fifty day simple moving average of $1.63 and a 200 day simple moving average of $1.60. BioRestorative Therapies has a 52 week low of $1.03 and a 52 week high of $3.67. The firm has a market capitalization of $10.24 million, a P/E ratio of -1.00 and a beta of 63.40.

Wall Street Analysts Forecast Growth

Separately, Roth Mkm upped their target price on BioRestorative Therapies from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.